| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |